Health & Biotech

There are clear signs the biotech sector is springing back to life after a disappointing 2022. The ASX XHJ is…

PAR’s randomised study showed that when osteoarthritic dogs were administered iPPS over eight weeks and 26 weeks.

Zelira's share price tripled this morning, after announcing that its diabetic nerve pain drug outperforms Big Pharma drug, Lyrica.

Special Report: MGC Pharmaceuticals’ Investigational Medicinal Product (IMP) CannEpil has been successfully imported and received by its first patients in…

Special Report: Incannex Healthcare has announced that three of the world’s top psychedelic therapy and science experts with significant media profiles…

Paediatric specialist Neurotech (ASX:NTI) has been granted an ethics approval to extend its Phase I/II clinical trial of NTI164.

After a challenging 2022, we are finally starting to see biotech show signs of life. Which ASX biotechs announced big…

Tissue Repair said the US FDA has cleared the company to progress to a Phase 3 clinical program for its…

Special Report: Wellnex Life is purchasing one of Australia’s largest topical pain relief brands for $22 million and undertaking an equity…

Volpara Health Technologies (ASX:VHT) posts strong FY23 results in a tough week for ASX health stocks impacted by macro economic…